硫普罗宁联用恩替卡韦对乙型病毒性肝炎患者肝功能的影响

Study on the Effects of Tiopronin Combined with Entecavir on Liver Function in Patients with Hepatitis B

目的探讨硫普罗宁联用恩替卡韦对乙型病毒性肝炎患者肝功能的影响。方法选取2019年1—12月阳山县人民医院收治的88例乙型病毒性肝炎患者作为研究对象,将采用恩替卡韦治疗的45例患者归为对照组,将采用硫普罗宁联合恩替卡韦治疗的43例患者归为观察组,连续治疗6个月。比较两组治疗前、治疗6个月时肝纤维化指标[血清层粘连蛋白(LN)、Ⅲ型前胶原(P-CⅢ)、血清透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)]、肝功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、γ-谷氨酰转肽酶(γ-GT)]及生活质量量表(SF-36)评分,并观察两组治疗期间不良反应发生情况。结果治疗6个月,两组LN、P-CⅢ、HA、Ⅳ-C水平下降,且观察组低于对照组,差异有统计学意义(P<0.05);治疗6个月,两组血清ALT、AST、γ-GT水平下降,且观察组低于对照组,差异有统计学意义(P<0.05);治疗6个月,两组生理功能、心理功能、躯体疼痛、总体健康、活力、社会功能、情感职能、精神健康评分高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论硫普罗宁联合恩替卡韦可有效改善乙型病毒性肝炎患者肝纤维化指标与肝功能,提高生命质量,且安全性较高。

Objective To investigate the effects of tiopronin combined with entecavir on liver function in patients with hepatitis B.Methods A total of 88 patients with hepatitis B admitted to People's Hospital of Yangshan County from January 2019 to December 2019 were selected as the research objects.A total of 45 patients treated with entecavir were classified as the control group,and 43 patients treated with tiopronin combined with entecavir were classified as the observation group,and the treatment was continued for 6 months.The liver fibrosis indexes[serum laminin(LN),typeⅢprocollagen(P-CⅢ),serum hyaluronic acid(HA),typeⅣcollagen(Ⅳ-C)before treatment and at 6 months of treatment between the 2 groups],liver function indicators[alanine aminotransferase(ALT),aspartate aminotransferase(AST),glutamyl transpeptidase(γ-GT)]and quality of life scale(SF-36)scores were compared,and the occurrence of adverse reactions during treatment in the group were observed.Results After 6 months of treatment,the levels of LN,P-CⅢ,HA andⅣ-C in the 2 groups decreased,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);after 6 months of treatment,the level of the serum ALT,AST andγ-GT decreased,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);the 2 groups were treated for 6 months,and the physical function,mental function,physical pain,general health,vitality,social function,emotion functional and mental health scores were higher than those before treatment.The observation group was higher than the control group,and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the observation group was not statistically significant compared with the control group(P>0.05).Conclusion Tiopronin combined with entecavir can effectively improve the liver fibrosis indexes and liver function of patients with hepatitis B,improve the quality of life,and has high safety.